Rob Citorik

Scientist and entrepreneur focused on innovation in genome engineering. Co-founder @TesseraTx. Tweets my own. #microbiology #synbio #biotech #genewriting

[Samuel Hume @DrSamuelBHume]

One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results

I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore

[Rob Citorik @rcitorik]

Looking forward to a great week of talks at #ASGCT2026!
#CGT #LNP, #genetherapy #geneticmedicine, #geneediting, #genewriting, #invivo, #AAV, #nucleicacids, #biotech, #startup, #therapeutics, #synbio, #raredisease, ...

[ASGCT @ASGCTherapy]

📢 The full 2026 Annual Meeting Abstracts Special Issue, including all late-breaking research, is officially live!

Explore the global advancements shaping the future of cell and gene therapy before we kick off #ASGCT2026 in Boston this Monday: https://t.co/NTugYaaSKN

[Tessera Therapeutics @TesseraTx]

Today, we're excited to share that we've received a grant from the Gates Foundation to advance our in vivo Gene Writing approaches toward a potential scalable cure for HIV. Read the full announcement here: https://t.co/sWLSE1I5WP

[Generate:Biomedicines @generate_biomed]

Introducing $GENB. We are now #NasdaqListed.

A meaningful milestone for our team — and an important step forward as we continue pioneering the AI revolution in drug design and development.

We are grateful to #TeamGenerate, our partners, and our investors who believed this work could be done.

[Rare Disease Day @rarediseaseday]

🌍 It’s #RareDiseaseDay 2026! 💜

Today we stand with the 300 million people living with a rare disease. Together, we’re showing our colours, raising awareness, and inspiring change by talking about what equity means to us.

👉 Read more: https://t.co/T0KRlbRCJX

[Generate:Biomedicines @generate_biomed]

Today we announced the pricing of our initial public offering at $16 per share, for gross proceeds of $400 million. Shares are expected to begin trading on @Nasdaq under the ticker $GENB.

Read the full news release → https://t.co/tCjzoBnjb5

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO @skathire covers the data. $VERV

Full video: https://t.co/PhLnfCQMJu

[Chris Fell @ChrisWFell]

So excited to share our new paper out today in @Nature. We repurposed R2 retrotransposons to create STITCHR, a tool that can make diverse edits in mammalian genomes including scarless multi-kilobase scale insertions

https://t.co/QCQlQmtyf3

[STAT @statnews]

“The word ‘science’ is in the US Constitution."
@BillNye gives a passionate speech at the #STATBreakthrough Summit.

[Ben Kleinstiver @BKleinstiver]

Interested in learning more about genome editing tool dev & their application to treat human diseases? 🧬 🏥 We're hiring graduating seniors who are seeking ~2 years of post-bac research experience. If you're interested in gaining experience in next gen medicines, please reach out and apply! Link 👇

[Chris Gibson @RecursionChris]

Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo.

I wrote about why these funds are so critical – and why this moment represents a call to action in the industry – in an op-ed for @statnews. Namely, NIH and SBIR funding led to the formation of leading biotechs and breakthroughs – from monoclonal antibody therapies, to the COVID-19 vaccine, to advances in CRISPR technology, AIDS treatments, and the HPV vaccine.

@RecursionPharma benefited from these funds, too – both to support the early research that led to our founding – and, after it was founded, receiving $3.5 million in NIH Small Business Innovative Research (SBIR) grants, which helped us get off the ground.

We’ve since raised more than 400 times our SBIR funding in private investment to advance our platform and improve the way drugs are discovered. Today, we are a $4 billion publicly-traded company with 8 therapeutics in clinical trials, more than 10 in advanced discovery, and R&D partnerships with leading pharmas.

And we believe that there are many other worthwhile biotech companies that need that same support to lead to the next great American medical breakthrough – and that we as an industry need to step up.

The Altitude Lab Fund – anchored by myself and biotech entrepreneur @dave_bearss – will provide:
● $100,000–$250,000 in pre-seed investment capital
● 12 months of lab and office space
● Admission to the competitive accelerator program run by our incubator, Altitude Lab in Salt Lake City, which includes exclusive mentorship and access to top tier national funds.

Learn more about the fund: https://t.co/2KyIVxzrBo

Read my op-ed: https://t.co/txUxP1pWr6

Check-out the story in Tech-Crunch: https://t.co/rlULivS9jz

CEO of a company caught in the SBIR-funding turmoil with a great impact score and interested in the Altitude Lab Fund? https://t.co/YFdvvCoWpq

[Rob Citorik @rcitorik]

@NikoMcCarty @arcinstitute @nvidia @AsimovPress Exciting advancements and great to see @AsimovPress always at the forefront!

[Martha Clokie @MarthaClokie]

Exciting update and developments for and within our @Leicester_Phage which will become the Becky Mayer Centre for Phage Research - we will be recruiting new staff early next year so please watch this space! https://t.co/ATPB3TPl9N

[Rob Citorik @rcitorik]

Congrats to the whole @TesseraTx team on the new investment from the @gatesfoundation - looking forward to seeing this accelerate the development of such an exciting program! #scd #sicklecell #geneticmedicine #invivo #biotech

[Tessera Therapeutics @TesseraTx]

Today, we announced we have entered into an agreement with the @gatesfoundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: https://t.co/dQZKfKgP1Z

[Tessera Therapeutics @TesseraTx]

Today, we announced we have entered into an agreement with the @gatesfoundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: https://t.co/dQZKfKgP1Z

[Rob Citorik @rcitorik]

@JessicaSacher Great thread and great thoughts! Audio has been huge for me as well, especially for making time/space for catching up (e.g., while doing the dishes). Still searching for the best text-to-speech, my experience Natural Reader > Speechify for science. Have you tried a variety?

[Rob Citorik @rcitorik]

@BowTiedBiotech @GeneInvesting @zhaoweiasu Need to double-down on getting a good EBV vaccine/booster, could think similar to VZV/shingles

[Rob Citorik @rcitorik]

@MarthaClokie Additionally, combo therapy feels like an easier step forward for practitioners to consider #phagetherapy vs a complete paradigm shift. Would love to see perspectives/models on whether this could also improve regulatory/reimbursement strategies!

[Moderna @moderna_tx]

Vaccines play a vital role in public health. Data from the @WHO show that vaccines prevent an estimated 3.5 to 5 million deaths each year from 20 different diseases.

This National Immunization Awareness Month, read more about the vaccines you need to protect yourself this fall, and how you can help protect yourself and your community from some of the most common respiratory illnesses this winter ⬇

https://t.co/ZmZM8Ph6Uq

[Rob Citorik @rcitorik]

Great resource from incredible pioneers- thank you @mooreorless62 (and the rest of the team you credited https://t.co/SHBqYo6VOr?), @moderna_tx, @coursera, and others for enabling broad accessibility to this important topic! 👏 #RNA #mRNA #geneticmedicine #free #onlinelearning

[Moderna @moderna_tx]

Today we announced a partnership with @coursera to launch mRNAs as Medicines, a three-module course designed by experts at Moderna that offers a comprehensive understanding of mRNA medicines, how they work and their potential applications.

mRNAs as Medicines is available for free to individuals who register as Coursera users.

Learn more: https://t.co/624Bo8AEUP